Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
Los Angeles, Nov 23, 2011 — Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trials for cancer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, California on December 10-13 , 2011.
Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
The results of this landmark study should be welcomed news to cancer patients across the world suffering from the debilitating effects of painful vertebral compression fractures,” said Dr. James Berenson, the study’s first author and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research in Los Angeles, CA. “It is documented that nearly one-fourth (24 percent) of patients with multiple myeloma, 14 percent with breast cancer, 8 percent with lung cancer and 6 percent with prostate cancer suffer painful vertebral compression fractures. With the results of this new randomized study, there is now clinical evidence of a treatment option for spinal fractures in cancer patients that can provide excellent relief of pain and improved quality of life.”
Los Angeles Non Profit Cancer Research Institute Hosts Beverly Hills Art Reception Featuring Rare Collections of Picasso, Miro and Dali and Never Before Seen Photographs of Marilyn Monroe.
Institute for Myeloma and Bone Cancer Research’s Fall Art Benefit offers an afternoon of art appreciation and auction, wine, and hors d’oeuvres at the Andrew Weiss Gallery in Beverly Hills, CA.
Roger Townsend makes the transition to IMBCR’s board of directors after serving two years on its Audit Committee.
REUNION – A Beer for Hope, now in its fourth year, today announced the release of its 2010 special brew, a Belgian-Style Scotch Ale.View pdf
IFFLA opening supports the work of the Institute for Myeloma & Bone Cancer Research
Benefits IMBCR Indian Film Festival takes place in L.A. on April 20
Manhattan Beach Sun January 2010
I-Newswire December 2009
CEO and founder, James R. Berenson, MD and IMBCR researchers will present the 9 papers, oral presentations and special sessions December 5-8, 2009 at the 51st ASH Annual Meeting and Exposition.
Video Feature July 2009
Dr. Jim Berenson is featured on KTLA-Channel 5’s prime time news segment from Emmy award winning news anchor, Emmett Miller as he follows the story of a courageous young police officer who is battling multiple myeloma.
Press Release January 2009
Press Release February 2009
Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors.
Press Release January 2009
FJC, a New York-based donor advised fund, is the latest organization to grant major funding to the “Cure Myeloma Project”, an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA
Press Release December 2008
Part of the Institute for Myeloma and Bone Cancer Research (IMBCR) “Cure Myeloma Project”, this funding will further explore new targeted therapeutic approaches against Multiple Myeloma with hopes of creating groundbreaking new treatments against malignant myeloma cells and devastating bone loss.
Press Release November 2008
Two oral presentations and three poster presentations will be offered by researchers from the Institute for Myeloma and Bone Cancer Research celebrating the 50th Annual Meeting of the American Society of Hematology (ASH). More Information…
Press Release June 2008
Myeloma Specialist Dr. James R. Berenson Featured on ReachMD’s “Clinician’s Roundtable” Read the Article…
XM Satellite Radio June 2008
Dr. Berenson featured on ReachMD XM Satellite Radio Channel 157 “Multiple Myeloma: Current Treatment Modalities” Free registration required.
I-Newswire.com March 2008
I-Newswire.com February 2008
I-Newswire.com February 2008
(I-Newswire) – Los Angeles, CA – MMSupport.net and the Institute for Myeloma and Bone Cancer Research are proud to announce the creation of “Ask the Expert”, a free online web-forum featuring Multiple Myeloma expert, Dr. James R. Berenson.
I-Newswire.com January 2008
Zhi-Wei Li, Ph.D. formerly of The Moffitt Cancer Research Center affiliated with the University of South Florida will lead scientific efforts for the Institute of Myeloma and Bone Cancer Research’s most recent research initiative, “The Cure Myeloma Project.”
Patientpower.com November 2007
We’ve been receiving hundreds of questions from myeloma patients. While we can’t answer them all, they do tend to cover common ground. We’ll address key topics in our next live webcast, the fourth in a series of 7 programs. Join us for our discussion with Dr. James Berenson, Founder, President and CEO of the Institute for Myeloma and Bone Cancer Research.
Coping with Cancer May/June 2007
New Developments in Multiple Myeloma Management
Positive results from numerous clinical trials have led to a rapid increase in the therapeutic options now available to effective care for people with multiple myeloma
Seattle Weekly March 7, 2007
More Helpful, Less Wicked
Old-school Pete’s Wicked Ale gang gets back together for a charity brew.
Former Pete’s sales manager Alan Shapiro contacted Slosberg about getting the Wicked gang back together for a charity project in her honor. All of the profits of the brew they have named “Reunion: A Beer for Hope” will benefit the Institute for Myeloma and Bone Cancer Research (IMBCR).
Myeloma Focus – Newsletter of the MMRF Spring 2007
MMRF Announces 2006 Compound Validation Award Winners
The MMRF is pleased to announce five Compound Validation Awards, each valued at $100,000 to researchers at five outstanding institutions. Read the article…
MorningNewsBeat.com March 2007
Retail News in Context, Analysis with Attitude by Kevin Coupe
Considering that cancer has been so much in the news the last two weeks, it was ironic that I got a chance to taste the new Reunion Imperial Brown Ale, described as a “beer for hope.”
IONlink August 2006
A Phase I/II Study of Trisenox®, VELCADE® and Ascorbic Acid in Relapsed/Refractory Multiple Myeloma. Read the article…
Oncology Times August 2006
Zoledronic Acid Extends Survival In Lung Cancer & Multiple Myeloma Patients With High Levels of Bone Metabolism. Read the article…
Winter 2005 Newsletter
Click here to download and view the Winter 2005 Newsletter.
American Cancer Society November 2005
Safety of Prolonged Therapy with Bortezomib in Relapsed or Refractory Multiple Myeloma Read the article…